Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Gavin Ling"'
Autor:
Andrew J. Doyle, Deborah Springell, Tina Dutt, Jessica Kenworthy, Gavin Ling, Michael Desborough, William Thomas, Joannes Hermans, Joost Vanveen, Tanya Cranfield, Edward Belsham, Quentin A. Hill, Will Lester, Marie Scully
Publikováno v:
Journal of Thrombosis and Haemostasis. 20:781-783
Publikováno v:
Blood. 140:5617-5618
Publikováno v:
Blood. 140:5586-5587
Autor:
Pu-Lin Luo, Gavin Ling
Publikováno v:
Medicine. 49:225-228
Inherited bleeding disorders (IBDs) encompass a large number of different but rare conditions that can lead to increased risk of bleeding. The most common IBDs are von Willebrand disease, haemophilia A and haemophilia B. The diagnosis of IBDs require
Autor:
Edward G. D. Tuddenham, Gavin Ling
Publikováno v:
British Journal of Haematology. 189:400-407
The foundation of haemophilia A therapy in the last 35 years has been critically dependent on isolation of the Factor VIII (FVIII) protein and discovery of the cDNA sequence of the FVIII gene, published in 1984. Identification of the FVIII sequence r
Autor:
Gavin Ling, Edward G. D. Tuddenham, Igor Kurtov, Tatiana Pospelova, Margarita Timofeeva, Nadezhda Zozulya, Marina Kosinova
Publikováno v:
Blood. 138:1040-1040
Background: FVIII replacement therapy is ineffective for severe haemophilia A (HA) patients who develop inhibitors to FVIII. Patients with intractable inhibitors currently require FVIII mimetics and/or bypassing agents to prevent bleeding. PEGylated
Autor:
Karen Breen, Gavin Ling, Deepti Radia, Natalia Curto-Garcia, Andrew J. Doyle, Donal P. McLornan, Claire N. Harrison, Beverley J. Hunt
Publikováno v:
British Journal of Haematology. 189
Publikováno v:
Blood. 136:9-9
Introduction Emicizumab (a bispecific antibody mimicking Factor VIIIa) has been authorised for use in the United Kingdom National Health Service (NHS) in severe hemophilia A patients with and without inhibitors since August 2019. The Summary of Produ
Publikováno v:
Haemophilia. 22:411-418
Aim Factor XI (FXI) concentrate is a pooled human plasma-derived factor concentrate used as replacement therapy for patients with FXI deficiency, which provides a predictable response and consistent haemostatic cover in emergency or elective situatio
Autor:
Beverley J. Hunt, Andrew J. Doyle, Gavin Ling, Claire N. Harrison, Donal P. McLornan, Natalia Curto Garcia, Deepti Radia, Karen Breen
Publikováno v:
Blood. 134:4183-4183
Introduction Myeloproliferative neoplasms (MPN) are associated with an increased rate of venous thromboembolism (VTE), which can be a major cause of morbidity and mortality especially in the more indolent diseases of polycythaemia rubra vera (PV) and